Autoantibody profiling to identify individuals at risk for systemic lupus erythematosus

Wandstrat, Amy E.; Carr-Johnson, Ferdicia; Branch, Valerie Klusas; Gray, Hillery F.; Fairhurst, Anna‐Marie; Reimold, Andreas M.; Karp, David R.; Wakeland, Edward K.; Olsen, Nancy J.

doi:10.1016/j.jaut.2006.09.001

Cited by 164 publications

(135 citation statements)

References 26 publications

Supporting

Mentioning

124

Contrasting

Unclassified

Order By: Relevance

“…In a recent study [3], measurement of autoantibodies including ANA, anti-dsDNA antibody and antichromatin antibody were carried out in patients with SLE, lupus syndrome, first degree relatives of these patients and normal controls. Among them lupus syndrome patients were found to have autoantibody profiles similar to those seen in SLE patients with the exception of antibodies to dsDNA and chromatin.…”

Section: Discussionmentioning

confidence: 99%

“…The most important diagnostic test for SLE is the detection of the presence of antinuclear antibodies (ANAs), because a negative result virtually rules out the possibility of SLE. However, they have low specificity for the diagnosis of SLE, because they are found in most systemic autoimmune diseases and even in healthy individuals [3,4]. Anti-dsDNA antibody has been used as a marker for disease activity, especially in renal disease.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The antichromatin antibodies can be useful as a diagnostic tool and disease activity marker of systemic lupus erythematosus in Koreans

Kim

Jeon

Choi

et al. 2008

Clinical Immunology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The antichromatin antibodies can be useful as a diagnostic tool and disease activity marker of systemic lupus erythematosus in Koreans

Kim

Jeon

Choi

et al. 2008

Clinical Immunology

View full text Add to dashboard Cite

“…There are obviously many critical issues which relate to the Mosaic of Autoimmunity, a number of which are already well illustrated in this issue. However, we refer to several recent papers for additional information on the panorama or spectrum of autoimmunity and immunopathology [26][27][28][29][30][31][32][33][34][35][36][37][38][39][40].…”

Section: Discussionmentioning

confidence: 99%

Novel molecular targets in the treatment of systemic lupus erythematosus

Crispín

Tsokos

2008

Autoimmunity Reviews

View full text Add to dashboard Cite

T cells from patients with systemic lupus erythematosus (SLE) display a number of biochemical abnormalities which include altered expression of key signaling molecules, heightened calcium responses, and skewed expression of transcription factors. These defects are involved in the altered behavior of SLE T cells and are probably central in the disease pathogenesis. The aim of this communication is to review the defects that have been consistently documented in SLE T cells, highlighting molecules and pathways that represent therapeutic targets. Keywordsautoimmunity; CD3ζ; pathogenesis; PP2A; systemic lupus erythematosus; therapyIn patients with autoimmune diseases, the immune system mounts full-scale responses against self constituents; it destroys self tissues using the same mechanisms it relies on when dealing with foreign noxious agents. Accordingly, the therapeutic actions of the drugs designed for the treatment of these conditions -whether conventional or biological-depend on their capacity to inhibit immune effector mechanisms. Thus, different degrees of immune suppression are implicit in their therapeutic capacity. The suppression of the immune system permits patients with autoimmune diseases to live better, longer lives, but is not able to cure them. Although in these conditions immune suppression is evidently useful, its use is always associated with the risk of infectious and malignant diseases.Patients with systemic lupus erythematosus (SLE) develop an immune response against a variety of ubiquitous antigens. Clinically, it manifests as a waxing and waning inflammatory disease whose intensity and organ involvement varies significantly. High concordance rates in monozygotic twins indicate that genetic factors play a major role in SLE development. In fact, polymorphisms of a number of genes have been linked to SLE. The mechanisms by which such polymorphisms contribute to disease expression are mostly unknown, however, the general assumption is that their presence causes functional changes in the immune response that make the system prone to autoreactivity when exposed to certain environmental or hormonal triggers. The risk imposed by the presence of each of the genetic factors associated

show abstract

“…In studies with a limited number of samples, investigators demonstrated that IgM autoantibodies predominated over IgG in patients with incomplete lupus erythematosus (at least 1 but less than 4 of the criteria for SLE (12 )). IgG usually predominates in SLE, however (13 ).…”

Section: Discussionmentioning

confidence: 99%

Screening Autoantibody Profiles in Systemic Rheumatic Disease with a Diagnostic Protein Microarray That Uses a Filtration-Assisted Nanodot Array Luminometric Immunoassay (NALIA)

et al. 2008

View full text Add to dashboard Cite

show abstract

Autoantibody profiling to identify individuals at risk for systemic lupus erythematosus

Cited by 164 publications

References 26 publications

The antichromatin antibodies can be useful as a diagnostic tool and disease activity marker of systemic lupus erythematosus in Koreans

The antichromatin antibodies can be useful as a diagnostic tool and disease activity marker of systemic lupus erythematosus in Koreans

Novel molecular targets in the treatment of systemic lupus erythematosus

Screening Autoantibody Profiles in Systemic Rheumatic Disease with a Diagnostic Protein Microarray That Uses a Filtration-Assisted Nanodot Array Luminometric Immunoassay (NALIA)

Contact Info

Product

Resources

About